Concise Prescribing Info
Ceftazidime pentahydrate 2 g, avibactam Na 500 mg
Complicated intra-abdominal infection & complicated UTI including pyelonephritis, hospital-acquired pneumonia including ventilator associated pneumonia, infections due to aerobic gram -ve organisms in patients w/ limited options in adults.
Dosage/Direction for Use
Adult 1 vial (2 g ceftazidime/500 mg avibactam) in 100 mL vol over 120 min infusion every 8 hr. Treatment duration: Complicated intra-abdominal infection 5-14 days. Complicated UTI including pyelonephritis 5-10 days. Hospital-acquired pneumonia including ventilator associated pneumonia 7-14 days. Renal impairment CrCl 31-50 mL/min 1,000 mg/250 mg every 8 hr, 16-30 mL/min 750 mg/187.5 mg every 12 hr, 6-15 mL/min 750 mg/187.5 mg every 24 hr, <6 mL/min 750 mg/187.5 mg every 48 hr.
Hypersensitivity to ceftazidime pentahydrate, avibactam Na, cephalosporins. Immediate & severe hypersensitivity (eg, anaphylactic reaction) to any other type of β-lactam agents (eg, penicillins, monobactams or carbapenems).
Special Precautions
Serious & occasionally fatal hypersensitivity reactions. Discontinue in case of severe hypersensitivity reactions. History of non-severe hypersensitivity to other β-lactam agents; patients w/ gram -ve aerobic infections. Consider diagnosis of Clostridium difficile-associated diarrhea in patients who present w/ diarrhea during or subsequent to administration. Prolonged use may result in the overgrowth of non-susceptible organisms (eg, enterococci, fungi). False +ve may occur w/ copper reduction methods (Benedict's, Fehling's, Clinitest). +ve direct antiglobulin test (DAGT or Coombs' test) seroconversion & potential risk of hemolytic anemia. Controlled Na diet. Concurrent treatment w/ high doses of cephalosporins & nephrotoxic drugs eg, aminoglycosides or potent diuretics (eg, furosemide). Renal impairment. May influence ability to drive & use machines. Pregnancy & lactation.
Adverse Reactions
Coombs' direct test +ve. Candidiasis (including vulvovaginal candidiasis & oral candidiasis); eosinophilia, thrombocytosis, thrombocytopenia; headache, dizziness; diarrhea, abdominal pain, nausea, vomiting; increased ALT/AST, blood alkaline, γ-glutamyltransferase & blood lactate dehydrogenase; rash maculopapular, urticaria, pruritus; infusion site thrombosis/phlebitis, pyrexia.
Drug Interactions
May adversely affect renal function w/ nephrotoxic medicinal products eg, aminoglycosides or potent diuretics (eg, furosemide). Possible antagonism w/ chloramphenicol. Potential alteration of elimination w/ probenecid.
MIMS Class
ATC Classification
J01DD52 - ceftazidime and beta-lactamase inhibitor ; Belongs to the class of third-generation cephalosporins. Used in the systemic treatment of infections.
Zavicefta powd for conc for soln for infusion
20 mL x 10 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in